Aardvark Therapeutics

Founder‑CEO Tien‑Li Lee, MD, leads a small senior team with relevant metabolic and regulatory backgrounds. Beneficial ownership shows meaningful founder alignment, and the board includes experienced industry figures.

Nonetheless, public‑market execution is still early and will be judged on navigating the current FDA dialogue, trial redesign if needed and financing choices.